دورية أكاديمية
Cellular and humoral immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in patients with hematologic malignancies
| العنوان: | Cellular and humoral immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in patients with hematologic malignancies |
|---|---|
| المؤلفون: | Jiménez, Moraima, Roldán, Elisa, Fernández-Naval, Candela, Villacampa, Guillermo, Martínez-Gallo, Mónica, Medina-Gil, Daniel, Peralta-Garzón, Soraya, Pujadas, Gemma, Hernández, Cristina, Pagès, Carlota, Gironella, Mercedes, Fox, María‐Laura, Orti, Guillermo, Barba, Pere, Pumarola, Tomás, Cabirta, Alba, Catalá, Eva, Valentín, Mercedes, Marín-Niebla, Ana, Orfao, Alberto, González, Marcos, Campins, Magda, Ruiz-Camps, Isabel, Valcárcel, David, Bosch, Francesc, Hernández, Manuel, Crespo, Marta, Esperalba, Juliana, Abrisqueta, Pau |
| المساهمون: | Generalitat de Catalunya |
| بيانات النشر: | American Society of Hematology |
| سنة النشر: | 2022 |
| المجموعة: | Digital.CSIC (Consejo Superior de Investigaciones Científicas / Spanish National Research Council) |
| مصطلحات موضوعية: | Clinical Trials and Observations, Immunobiology and Immunotherapy |
| الوصف: | Recent studies have shown a suboptimal humoral response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger RNA (mRNA) vaccines in patients diagnosed with hematologic malignancies; however, data about cellular immunogenicity are scarce. The aim of this study was to evaluate both the humoral and cellular immunogenicity 1 month after the second dose of the mRNA-1273 vaccine. Antibody titers were measured by using the Elecsys and LIAISON anti–SARS-CoV-2 S assays, and T-cell response was assessed by using interferon-γ release immunoassay technology. Overall, 76.3% (184 of 241) of patients developed humoral immunity, and the cellular response rate was 79% (184 of 233). Hypogammaglobulinemia, lymphopenia, active hematologic treatment, and anti-CD20 therapy during the previous 6 months were associated with an inferior humoral response. Conversely, age >65 years, active disease, lymphopenia, and immunosuppressive treatment of graft-versus-host disease (GVHD) were associated with an impaired cellular response. A significant dissociation between the humoral and cellular responses was observed in patients treated with anti-CD20 therapy (the humoral response was 17.5%, whereas the cellular response was 71.1%). In these patients, B-cell aplasia was confirmed while T-cell counts were preserved. In contrast, humoral response was observed in 77.3% of patients undergoing immunosuppressive treatment of GVHD, whereas only 52.4% had a cellular response. The cellular and humoral responses to the SARS-CoV-2 mRNA-1273 vaccine in patients with hematologic malignancies are highly influenced by the presence of treatments such as anti-CD20 therapy and immunosuppressive agents. This observation has implications for the further management of these patients. ; The authors also thank the Cellex Foundation for providing research facilities and equipment and the CERCA Programme/Generalitat de Catalunya for institutional support. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | unknown |
| العلاقة: | Publisher's version; http://dx.doi.org/10.1182/bloodadvances.2021006101Test; Sí; e-issn: 2473-9529; Blood Advances 6(3): 774-784 (2022); http://hdl.handle.net/10261/282782Test; http://dx.doi.org/10.13039/501100002809Test |
| DOI: | 10.1182/bloodadvances.2021006101 |
| DOI: | 10.13039/501100002809 |
| الإتاحة: | https://doi.org/10.1182/bloodadvances.2021006101Test https://doi.org/10.13039/501100002809Test http://hdl.handle.net/10261/282782Test |
| حقوق: | open |
| رقم الانضمام: | edsbas.2751633E |
| قاعدة البيانات: | BASE |
| DOI: | 10.1182/bloodadvances.2021006101 |
|---|